(United States, Nevada, Las Vegas), DelveInsight’s, “Cardiovascular Calcification Pipeline Insight, 2023,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cardiovascular Calcification Pipeline Report
-
Over 6+ companies and 6+ pipeline drugs in Cardiovascular Calcification are in various stages of development, and their anticipated acceptance in the Cardiovascular Calcification market would significantly increase market revenue.
-
Leading Cardiovascular Calcification companies developing novel drug candidates to improve the Cardiovascular Calcification treatment landscape include Sanifit, Inositec, Sanofi, Dong-A ST, and many others
-
Promising Cardiovascular Calcification pipeline therapies in various stages of development include SNF 472, INS-3001, and many others
Cardiovascular Calcification Overview
Cardiovascular calcification is a process in which mineral deposits form in vessel walls and heart valve leaflets and can lead to tissue stiffening, plaque rupture, and heart failure. Several biological processes contribute to cardiovascular calcification, including extracellular vesicle release, matrix remodeling, loss of mineral-deposition inhibition, impaired mineral resorption, oxidative stress, mitochondrial dysfunction, inflammation, and stem and progenitor cell programs. It is a commonly observed but incompletely understood mechanism of increased atherosclerotic plaque instability and accelerated aortic valve stenosis.
Cardiovascular Calcification Pipeline Analysis: Drug Profile
SNF 472: Sanifit
SNF472 is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification. Sanifit’s SNF 472 blocks calcification, with action independent of Ca/Phosphate levels.
INS-3001: Inositec
INS-3001 is a cardiovascular calcification inhibitor, based on myo-inositol hexaphosphate (IP6). It is being developed to treat a number of diseases driven by cardiovascular calcification, including aortic valve stenosis. The molecule has demonstrated the ability to significantly inhibit the calcification process in preclinical studies.
Discover more about the emerging Cardiovascular Calcification drugs @ Cardiovascular Calcification Treatment Drugs
Cardiovascular Calcification Pipeline Therapies and Key Companies
-
SNF 472: Sanifit
-
INS-3001: Inositec
-
NS-3001: Inositec
And many others
Cardiovascular Calcification Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
-
Route of Administration
Route of Administration
Cardiovascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical.
-
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the Cardiovascular Calcification Pipeline Report
-
Coverage: Global
-
Key Cardiovascular Calcification Companies: Sanifit, Inositec, Sanofi, Dong-A ST and many others
-
Key Cardiovascular Calcification Pipeline Therapies: SNF 472, INS-3001, and many others
Find out more about the Cardiovascular Calcification treatment options in development @ Cardiovascular Calcification Clinical Trials
Table of Contents
1. Cardiovascular Calcification Introduction
2. Cardiovascular Calcification Executive Summary
3. Cardiovascular Calcification Overview
4. Cardiovascular Calcification Pipeline Therapeutics
5. Cardiovascular Calcification Late-Stage Products (Phase III)
6. Cardiovascular Calcification Mid-Stage Products (Phase II)
7. Cardiovascular Calcification Early Stage Products (Phase I/II)
8. Cardiovascular Calcification Preclinical Stage Products
9. Cardiovascular Calcification Discovery Stage Products
10. Cardiovascular Calcification Therapeutic Assessment
11. Cardiovascular Calcification Inactive Products
12. Cardiovascular Calcification Collaborations Assessment- Licensing / Partnering / Funding
13. Cardiovascular Calcification Unmet Needs
14. Cardiovascular Calcification Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services